Skip to main content
SpringerLink
Log in

Schwerpunkt "Uterusmalignome"

Personalisierte Systemtherapie des Endometriumkarzinoms

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, 2018, AWMF Registernummer: 032/034-OL

  2. Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73

  3. León-Castillo A et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020;38(29):3388-97

  4. Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) https://clinicaltrials.gov/ct2/show/NCT03603184 abgerufen am 26 Mai 2021

  5. A Study to Evaluate Dostarlimab Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY) https://clinicaltrials.gov/ct2/show/NCT03981796 abgerufen am 26 Mai 2021

  6. Fader AN et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res. 2020;26(15):3928-35

  7. Marabelle A et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10

  8. Antill YC et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol. 2019;37(15_suppl):5501

  9. Konstantinopoulos PA et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786-94

  10. Oaknin A et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. ESMO. 2020;Abstr LBA36

  11. Makker V et al. Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial. SGO. 2020;Abstr 10

  12. Makker V et al. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. SGO. 2021;Abstr. 11512

  13. Mirza MR et al. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial. ESMO. 2020;Abstr LBA28

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Deutschland

    Philipp Hederich

Authors
  1. Philipp Hederich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hederich, P. Personalisierte Systemtherapie des Endometriumkarzinoms. InFo Hämatol Onkol 24, 23–26 (2021). https://doi.org/10.1007/s15004-021-8695-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8695-6

Search

Navigation